Clinical Trial Update: Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating capivasertib plus paclitaxel as first-line treatment for locally advanced or metastatic triple-negative breast cancer is currently acti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Capivasertib (capivasertib)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: AstraZeneca | Conditions: Triple Negative Breast Neoplasms | Phase 3 | Status: ACTIVE_NOT_RECRUITING